🔴 Ionis Pharmaceuticals is trading 11.5% down in pre-market after CARDIO-TTRansform failed its primary endpoint

Ionis Pharmaceuticals is trading 11.5% down at $51.40, with the decline appearing to extend pressure from the July 9 announcement that the Phase 3 CARDIO-TTRansform study of eplontersen failed its primary endpoint.

• No new company-specific negative announcement was identified for September 8, 2026.
• Ionis Pharmaceuticals announced FDA approval of Zanvastro on September 3, while broader markets were weaker overnight.
• The move is substantially larger than the provided major-index declines.